Revenue qualityDanger
매출 흑자인데 영업CF 적자 (OCF/매출 -2400%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Cronos Group
CRON-US · Nasdaq$3.41+3.02%
2026-08-24 closeCronos Group — what's the grade? And what signals are flashing today?
The grade and valuation bands are below — free to read.
Loading chart…
CloseMA20MA60MA120
AI Insight
Why these signals fired — only backtest-proven edge, told honestly
Why this signalSignal guide
Moving-average alignment
Yes · score 0.72
New high + volume — the real recordrecord · not a prediction
Not this one stock, but every new-high-plus-volume pick we actually published (US market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-25)
Last 30 sessions
257 picks
Next-day win rate
41%
Avg next-day
-0.41%
vs market
-0.58%p
Beat the market on 40.6% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
08-21 42.9%08-20 57.1%08-19 11.1%08-18 75%08-17 50%08-14 66.7%08-13 16.7%08-12 25%08-11 45.5%08-10 23.1%08-07 54.5%08-06 46.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Trade plan
Decide the exit before you enter. Set what you are willing to lose first, and the share count follows — so you know the worst case before you buy.
Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.
This is a calculator, not advice, and it does not promise any outcome. You choose the stop and target — the button values (ATR, recent low/high) are observations from past prices. Actual fills depend on the order book and liquidity.
Valuation Grades
Relative to 752 건강관리 peers · not investment advice
A+
Overall: 건강관리 65/752 · top 9%
Factor composite · relative position in sector
Financial safety
Reference indicatorAs of 1997Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -14.09
Distress
Grey
Safe
- Altman Z''
- -14.09
- Beneish M-Score
- —
- Sloan accrual
- 171.81%
Statistical flag unavailable
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
6/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score6/9
Profitability
- Positive ROAPass
- Positive OCFNot passed
- Improving ΔROAPass
- Accruals (OCF > net income)Not passed
Leverage & liquidity
- Lower debtPass
- Higher current ratioPass
- No new sharesPass
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverPass
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Forensic signals
Anomaly and structural signals observed in the financial statements.
Balance sheetDanger
자본잠식 — 자본총계가 마이너스입니다. 부실 위험을 나타내는 사실 지표입니다.
Margin trendWarning
영업외손익 급변 (영업이익 대비 453% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.
Factual information, not investment advice.
Industry structure
USAs of 2026-08-25건강관리
This stock is in 건강관리: revenue rank 540 of 547, share 0%.
540 / 5470%revenue share
Who dominates this industry?
- 1CVS Health14.1%
- 2McKesson13.6%
- 3Cigna9.4%
- 4Cardinal Health8.4%
- 5Centene6.2%
- 6Cronos Group0%
Concentration
DistributedCR3 37.1%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 159.97
- Direction
- 축소
- Level
- 넓음
- Years
- 21
Value lens
- P90/P10
- 23.8
- Median P/B
- 3.04
- Level
- 넓음
- n
- 465
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- -5,360%
- Interest coverage
- -107.2x
- Return on equity (ROE)
- —
Operating margin −5pp
Operating lossInterest coverageBase -107.2x adverse case -107.3x
Return on equity (ROE)Base — adverse case —
Revenue −15%
Interest coverage riskInterest coverageBase -107.2x adverse case -91.1x
Return on equity (ROE)Base — adverse case —
Interest rate +2pp
Interest coverage riskInterest coverageBase -107.2x adverse case -17x
Return on equity (ROE)Base — adverse case —
Interest coverage limit
Already below the limit by 5,410ppInterest coverage limit at an operating margin of 50%
Interest expense coverage threshold
Financials at a glance
Cronos Group's latest results and balance sheet. The bars track the last three periods.
Connections
AI-extracted related companies · for reference
Customers
Competitors
Canny GrowthTilray BrandsAurora CannabisCanopy GrowthSNDLCuraleaf HoldingsTrulieve CannabisCresco LabsGreen Thumb IndustriesOrganigram GlobalHexo CorpCannTrust Holdings
Same theme
Recent filings
Filings for overseas stocks are on the way. For now we cover Korean stocks only.
Signal history (last ~2 years)
Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.
52-week high breakout×1
26-08-24·
New MA alignment×4
26-08-06·26-07-24+17.8%26-07-20+12.5%26-06-29+0%
“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy